MyChem’s nucleotide synthesis methods are highly complementary to Maravai’s TriLink mRNA technologies Increases capabilities serving the high-growth cell and gene…
Brings Significant Operational Experience in Building Therapeutic Drug Development BusinessesTUCSON, Ariz., Jan. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc.…
MONMOUTH JUNCTION, N.J., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the…
Amryt Announces Oleogel-S10 EMA Regulatory Update Ad-Hoc Expert Group to provide independent EB specific expertise and advice DUBLIN, Ireland, and…
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 28, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company…
VANCOUVER, British Columbia, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB:…
University Hospital Brandenburg an der Havel January 28, 2022 Major German University Hospital secures long-term access to the latest health…
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing…
Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new U.S.-based AAV Manufacturing and Innovation Business Homology…
The companies will continue with their exclusive agreements, including for commercialization of their current portfolioCAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE…